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The group-specific antigens Pr55gag of human immunodeficiency virus type-1 (HIV-1) self-assemble into noninfectious
virus-like particles (VLP) that are released from various eucaryotic cells by budding. Deletion analysis of Pr55gag mutants
revealed three domains into which sequences of the third variable domain V3 or the CD4-binding domain of the gp120 external
glycoprotein can be inserted without destroying the capacity of the chimeric proteins to assemble to VLP. Immunization of
rabbits with different types of purified chimeric VLP without adjuvants raised a strong antibody response to the Pr55gag
carrier component. The magnitude of the antibody response to the inserted gp120 epitopes strictly depended on their position
within the gag polyprotein. These antisera exhibited only weak neutralizing activity. However, BALB/c mice immunized by
different routes with different types of chimeric Pr55gag/V3 VLP without adjuvants developed a strong MHC class I (Dd)-
restricted, cytolytic CD8/ T-cell (CTL) reactivity against a known epitope within the V3 domain. When the recombinant
antigen was emulsified in mineral oil (incomplete Freund’s adjuvant) or adsorbed in aluminium hydroxide, its immunogenicity
for CTL was drastically reduced or completely abrogated. The magnitude of the V3-specific CTL response was not influenced
by the position of the V3 domain within the Pr55gag-carrier moiety; the flanking residues, hence, did not influence processing
of the exogenous antigen for MHC class I-restricted peptide presentation. These results indicate ways for the rational
design and optimal delivery of CTL-stimulating HIV candidate vaccines. q 1996 Academic Press, Inc.
INTRODUCTION apoptosis (Weinhold et al., 1989; Amadori et al., 1992;
Siliciano et al., 1988; Tyler et al., 1989).
New insights into the pathogenesis of the human im-
Preventive HIV-1 candidate vaccines should thereforemunodeficiency virus type-1 (HIV-1) suggest that the cell-
focus on the priming of an effective HIV-specific CTLmediated immune response plays a crucial role in con-
response and try to avoid the induction of potential ad-trolling the acute phase of infection (Koup and Ho, 1994;
verse side effects such as enhancing antibodies. Consid-Koup et al., 1994). Studies on long-term nonprogressors
ering the variability and genetic instability of HIV-1, a(Huang et al., 1995; Cao et al., 1995), people at high
careful selection of highly conserved, immunologicallyrisk (Rowland-Jones et al., 1995), HIV-infected children
relevant HIV epitopes and a favorable as well as safe(Bryson et al., 1995), and health care workers exposed
delivery of the antigens to the immune system is re-to HIV contaminated material (Pinto et al., 1995) indicate
quired.that a CD8/ CTL response is closely associated with the
Priming of cytolytic T cells in vivo has been describedcontrol of viral replication or even with the clearance
for recombinant live viruses (Cox et al., 1993), proteinsof an HIV infection (Paul-WE, 1995). Whether or not the
associated with detergent-type adjuvants such as lipo-humoral immune response contributes to protection in
somes (Nair et al., 1992; Reddy et al., 1992), ISCOMsthe human situation in vivo is not completely clear to
(Heeg et al., 1991) or saponin QS-21 (Newman et al.,date. There are even in vitro experiments that link severe
1992), and attenuated HIV virions (Daniel et al., 1992;immune dysfunctions such as graft-versus-host like dis-
Almond et al., 1995). Safety considerations have so fareases or an enhancement of HIV infection to the pres-
precluded application in humans. Particulate carriersence of nonneutralizing envelope-specific antibodies
mainly based on heterologous viral antigens or the yeast(Robinson, Jr. et al., 1989a,b; Takeda et al., 1992; Young,
TYA gene product support the induction of a strong CTL1988; Golding et al., 1989). The antigen itself has also
response in the absence of adjuvants or a replicatingbeen implicated in HIV pathogenesis by rendering CD4/
vector (Layton et al., 1993). However, most of these heter-cells unresponsive to antigenic stimulation or inducing
ologous antigen delivery systems suffer from the presen-
tation of a limited number of epitopes and do not allow1 To whom correspondence and reprint requests should be ad-
the presentation of complex foreign antigens.dressed. Fax: //49 (0) 941 944 6402. E-mail: Ralf.Wagner@kliuik.
uniRegensburg.de. Based on growing insight into the molecular events
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regulating the morphogenesis of HIV, we developed an were obtained from the American Type Culture Collection
(ATCC, Rockville, U.S.A.).autologous, nonreplicating, and safe antigen delivery
system. This carrier system is based on the HIV-1 group-
specific antigen (Pr55gag) (Wagner et al., 1994, 1995; Wolf HIV-sequence
et al., 1994), which contains different T-helper cell-de-
fined and CTL-defined epitopes (Nixon et al., 1988; Gotch All amino acid positions given in the text refer to the
Hxb2 sequence.et al., 1990; Phillips et al., 1991). If produced in an appro-
priate eukaryotic expression system, the HIV-1 group-
specific antigen self-assembles into immunogenic, Monoclonal antibodies
noninfectious VLP (Wagner et al., 1992a). Minimal re-
quirements for this process are (i) the aminoterminal myr- The V3-specific murine monoclonal antibody recogniz-
ing a central motive of the V3-loop region (RIQRGPGRA-istoylation of the gag precursor (Gottlinger et al., 1989),
(ii) a transport-associated domain located in the p17 ma- FVTIGKI) was purchased from DuPont (Nea 9301). The
Pr55gag-specific monoclonal antibody used has beentrix portion of Pr55gag (Bergmann et al., 1993), as well as,
(iii) at least three assembly domains, one located in the mapped to amino acids 307–336 within Pr55gag (mab 16/
4/2) (Wolf et al., 1990). In some experiments, spleen cellsmatrix moiety (Niedrig et al., 1994) and two within the
carboxy-terminal portion of p24 (Mammano et al., 1994; from immunized mice were treated for 30 min at 47 twice
with anti-CD4 mab GK1.5 or anti-CD8 mab followed byvon Poblotzki et al., 1993). Determinants in the central
part of p24 and overlapping parts of the p6 domain within an incubation for 45 min at 377 with low-tox-M-rabbit
complement (Cedarlane, Hornby, Canada).the Pr55gag are dispensable for the early steps of HIV-
morphogenesis (Wagner et al., 1994). Replacing these
sites by foreign sequences such as the third variable Construction of chimeric Pr55gag
domain V3 of gp120, known to include a murine and
human CTL epitope (Takahashi et al., 1988), and express- The construction of chimeric Pr55gag-genes is based
on three previously described gag mutants referred toing the chimeric antigens in the vaccinia virus expression
system did not significantly affect the capacity of the as plin8Pr55D2, plin8Pr55D3, and plin8Pr55F4, whereas
plin8 is a derivative of a commercial pUC8 vectoraltered polypeptides to form VLP (Wagner et al., 1994).
Here, we describe the large scale production and purifi- (Wagner et al., 1993, 1994). Two annealed synthetic oligo-
nucleotides encoding the complete V3LAI-loop sequencescation of different chimeric VLP from a baculovirus-based
insect cell expression system allowing the delivery of the were directly inserted into unique XhoI/SacI sites of the
mutant Pr55gag genes to create the plin8Pr55V3-2, -3,V3 domain and a linear portion of the discontinuous CD4-
binding domain within gp120 to the immune system and -4 (Fig. 1). A linear portion of the CD4-binding domain
including the flanking cysteine residues (CD4BR; 196 bp)(Lasky et al., 1987). The capacity of the chimeric VLP to
induce a humoral and cell-mediated immune response was amplified from a HIV-1 provirus clone (Hxb2) using
the 5*-primer 5*-GAG GGA TCC GCT CGA GGG TCA AATdirected against the carrier component and the pre-
sented epitopes is described. AAC ACT GAA GGA AGT-3* and the 3*-primer 5*-GAG
AAG CTT ATC GAT CCG AGC TCA CCA TCT CTT GTT
AAT AGC AGC CC-3*. Alternatively, a truncated versionMATERIALS AND METHODS
of the CD4-binding region (CD4BRs, 78 bp) lacking the
Media, cells, and viruses
cysteine residues was amplified by using the primer pair
5*-CAC ACA GGA TCC GCT CGA GCA AGA ATA AAAWild-type and recombinant baculoviruses Autographa
californica nuclear polyhedrosis virus (AcNPV) were CAA ATT ATA-3* (5*-primer) and 5*-CAC ACA CAA GCT
TCC GAG CTC TCT AAT TTG TCC ACT GAT-3* (3*-propagated and titrated on Spodoptera frugiperda (SF9)
insect cells in TC100 medium supplemented with 10% primer). Both amplified DNA sequences were flanked by
a XhoI and a SacI site. This allowed a direct subcloningFCS (GIBCO-BRL, Grand Island, U.S.A.) as described
(Smith et al., 1985). For large scale preparation of recom- of the selected subgenic fragments into plin8Pr55D2,
plin8Pr55D3, and plin8Pr55F4, resulting in the plasmidsbinant antigens from serum-free cell culture superna-
tants (SF900; GIBCO-BRL, Grand Island) HighFive cells plin8Pr55CD4BR-2, -3, -4 and plin8Pr55CD4BRs-2, -3,
and -4. Finally, we combined the V3 domain and thederived from Trichoplusia ni egg cell homogenates (In-
vitrogen) were used for the infection with the recombi- CD4BR into one gag-gene by replacing the 436-bp BglII/
SalI fragment of plin8Pr55V3-2 by the correspondingnant baculoviruses. Human immunodeficiency virus type-
1 (HIV-1 LAI) was grown and titrated on MT-4 and H9 BglII/SalI fragment of plin8Pr55CD4BR-4. The resulting
plasmid was referred to as plin8Pr55V3/CD4BR (Fig. 1).cells obtained from the ATCC (Rockville, U.S.A.) in
RPMI1640 supplemented with 10% FCS, L-Glutamine, All PCR-amplified, -inserted, or -exchanged DNA-se-
quences, including the flanking regions, were verified byand antibiotics. The H-2d B lymphoma cell line A20
(TIB208) and the H-2d mastocytoma cell line P815 (TIB64) double-stranded DNA sequencing.
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Construction of recombinant baculoviruses buffer (125 mM Tris/HCl, pH 6.8, 2% (w/v) SDS, 10% (w/
v) b-mercaptoethanole, 10% (w/v) glycerine, 1 mM EDTA,
After subcloning of the EcoRI/BclI fragments of the 0.005% (w/v) bromophenol blue). Solubilized preparations
plin8Pr55 derivatives into the EcoRI/BamHI site of the of the chimeric proteins were further purified by a contin-
baculovirus transfer vector pVL1392 (Invitrogen, U.S.A.), uous elution polyacrylamide gel electrophoresis by using
recombinant baculoviruses were established and plaque a PrepCell column (model 491; Bio-Rad, Germany) ac-
purified according to standard procedures (Smith et al., cording to the manufacturers instructions.
1985). The resulting baculoviruses were referred to as
AcPr55V3-2, -3, and -4, AcPr55CD4BR-2, -3, and -4, and Electron microscopy
AcPr55CD4BRS-2, -3, -4, and AcPr55V3/CD4BR, respec-
SF9 cells (108) were harvested 3 days after infectiontively.
with the recombinant AcNPVs (m.o.i.  10). Specimens
for ultrathin sectioning were prepared as describedDetection and quantification of chimeric proteins
(Wagner et al., 1994). Sections of 25 to 75 nm thickness
Chimeric proteins expressed in infected insect cells were cut with a diamond knife and mounted on uncoated
(m.o.i. 10 per cell) and preparations of VLP from serum- copper grids. The sections were poststained with 100
free cell culture supernatants was analyzed by conven- mmol lead (II) citrate, pH 12.6. All pictures were taken
tional Western blot analysis. Yields of the chimeric pro- with Siemens Elmiskop 101 electron microscope. The
teins synthesized in the infected cells and secreted in magnification was calibrated with a cross line grating
the form of VLP into the cell culture supernatant were replica. Presence or absence of AcNPVs in single frac-
determined after sonification using a commercial antigen tions obtained from the sucrose gradient was assessed
sandwich assay (Abbott, U.S.A.). For control, the amounts by negative stain electron microscopy (Osterrieder et al.,
of secreted and purified VLP were also determined with 1995). For that purpose, purified VLP were adsorbed to
a commercial assay for total protein quantification ac- grids after fixation with 2% glutaraldehyde. After three
cording to the manufacturers instructions (Bio-Rad, Ger- washes, grids were contrasted with phosphoric tungstic
many). acid and examined in the electron microscope.
Animal experiments and immunizationAnalysis and purification of VLP and recombinant
proteins Rabbits (three animals per group) were immunized
three times (0, 4, 8 weeks) intramuscularly (i.m.) with 50Serum-free supernatants of HighFive cells infected
mg of the chimeric VLP particles or purified proteins inwith the described recombinant baculoviruses were col-
4-week intervals in the absence of adjuvant. As a control,lected 3–5 days p.i. Concentration of VLP from pre-
antigens were administered i.m. using complete Freund’scleared culture supernatant (3300 g) was achieved as
adjuvant (CFA) for the first immunization and incompletedescribed (Wagner et al., 1992a). Two-milliliter aliquots
Freund’s adjuvant (IFA) for the following booster injection.of the concentrated material were layered onto a 12-ml
Blood sampled 10 days after each immunization was10–60% sucrose gradient in 10 mM phosphate buffer, pH
used to prepare the antisera. BALB/cJ mice (H-2d) were7.5, containing 0.15 M NaCl and centrifuged at 100,000 g
bred under standard-pathogen-free conditions in the ani-for 20 hr at 47. Fractions (0.5 ml) were collected, diluted
mal colony of the University of Ulm (Ulm, FRG). Male andby PBS, and VLP were pelleted at 16,000 rpm for 40 min
female mice were used at 12 to 16 weeks of age. Miceat 47 in an Eppendorf centrifuge. The antigen prepara-
(five animals per group) were injected intraperitoneallytions were resuspended in 200 ml 20 mM Tris–HCl, pH
(i.p.) or subcutaneously (s.c.) into the base of the tail with7.5, 150 mM NaCl, 2 mM EDTA and analyzed by conven-
the indicated dose of chimeric VLP without adjuvants. Intional Western blot analysis following separation of the
some experiments, the chimeric particles were emulsi-proteins on a denaturing SDS 12%–PAGE. Antigen from
fied in IFA or adsorbed to aluminium hydroxide (alum)all fractions was quantified exactly using a commercial
(Schirmbeck et al., 1994).p24-specific antigen sandwich assay (Abbott, U.S.A.).
Triplicate infection experiments followed by sucrose sed-
ELISA
imentation analysis of the cell culture supernatants
yielded standard errors which were always less than 8% Micro-ELISA plates (Greiner, Frickenhausen, Ger-
many) were coated with either 80 ng recombinant p24,of the means (pg p24CA). Fractions that were—ac-
cording to negative stain electron microscopical exami- 80 ng rgp120, 300 ng of a V3 peptide (amino acid 296–
333), or 300 ng of a peptide representing a linear portionnation—almost free of contaminating AcNPVs have
been pooled and used for the immunization. To compare of the CD4-binding region (amino acid 419–444) per well
in 50 ml 0.05 M sodium carbonate buffer, pH 9.5, at 47.the immunological properties of the VLP with the corre-
sponding soluble form of the chimeric gag proteins, puri- Serial dilutions of the sera in PBS with 3% FCS and 2%
Tween-20 were added to the coated wells. After incuba-fied VLP were disintegrated by the addition of a loading
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tion for 2 hr at 377 and three washing steps, bound anti- release 0 spontaneous release)/(total release 0 sponta-
neous release)] 1 100. Total counts were measured bybody was detected with horseradish peroxidase-conju-
gated anti-rabbit antibody (Dakopatts, Copenhagen, Den- resuspending target cells. Spontaneously released
counts were always less than 20% of the total counts.mark) at a dilution of 1:1000, followed by incubation with
o-phenylendiamine–0.01% hydrogen peroxide in phos- Data shown are the means of triplicate cultures. The
SEM of triplicate data was always less than 25% of thephate-buffered saline (pH 6.0). The reaction was stopped
by adding 1 M H2SO4 and read at 492 nm. Values above mean.
the mean optical density/3 SD of negative controls were
considered positive. RESULTS
Expression and biochemical characterization ofHIV-1 neutralization assays
chimeric Pr55gag particles
Sera from rabbits were obtained after three immuniza-
Two domains of Pr55gag, i.e., aa 211–241 within p24CA
tions and used for the neutralization assay. Virus stocks
and aa 436–471 within the p6LI moiety, are not involved
were titrated in MT-4 cells by serial twofold dilution steps
in assembly and budding of recombinant VLP (Wagner
(12 replicas per dilution). Fifty infectious particles per 50
et al., 1994). These domains were replaced, either by the
ml were mixed by shaking in 96-well microtiter plates
complete 37 amino acid V3 loop sequence including the
either with 50 ml medium (negative control) or with 50 ml
flanking cysteine residues (Wagner et al., 1992b) or by
sterile filtered, heat inactivated serum (30 min, 567) at
two types of a linear portion of the discontinuous CD4-
different dilutions (in triplicate). After 60 min incubation
binding region (CD4BR; 23 and 55 residues, respectively)
(377, 5% CO2 , 98% humidity), 100 ml of MT-4 cell suspen- (Lasky et al., 1987). Alternatively, these epitopes were
sion (5 1 104 cells/ml) were added to each well. After 2
fused to the carboxy-terminus of the complete gag-pre-
hr of virus adsorption, 80% of the culture supernatant
cursor. In addition, we generated a chimeric gag mole-
was removed and 160 ml of fresh medium was added to
cule, in which the V3 domain replaced amino acids 211–
each well. Plates were then incubated for 6 days, after
241 and the CD4BR was fused to the carboxy-terminus
which the cells were scored by using a microscope for
of the Pr55gag precursor (Fig. 1).
the presence of characteristic cytopathic effect. In addi-
Recombinant baculoviruses expressing the indicated
tion, cell culture supernatants were analyzed for virus
chimeric proteins were established and referred to as
release by a commercial p24 sandwich assay (Abbott,
AcPr55V3-2, AcPr55V3-3, AcPr55V3-4, or AcPr55CD4BRs-2,
U.S.A.) and confirmed by a nonradioactive RT analysis
AcPr55CD4BRs-3, AcPr55CD4BRs-4, or AcPr55CD4BR-2,
(Boehringer Mannheim, Mannheim, Germany). Neutral-
AcPr55CD4BR-3, AcPr55CD4BR-4 and AcPr55V3/CD4BR
ization titers are expressed as the highest serum dilution
(Fig. 1). Correct expression of the chimeric Pr55gag pro-
that inhibited p24 production and release by more than
teins was demonstrated in lysates of infected HighFive
90% as compared to the negative control.
insect cells by Coomassie staining and immunoblot anal-
ysis (Figs. 2A and 2B). Recombinant proteins with a cal-Cytotoxic assay
culated molecular weight ranging from 53 to 58 kDa were
identified, which were dependent on the length of theLymphoid cells from the spleen or the inguinal lymph
nodes were aseptically prepared from immunized mice replaced sequences. These protein species were not
detectable in lysates of wt-AcNPV-infected or uninfected5 to 20 days postimmunization. Cells were suspended in
a-MEM tissue culture medium (GIBCO-BRL, Grand Is- cells (Fig. 2A). Although comparable amounts of recombi-
nant proteins were detected in all cell lysates (1–1.5 mgland, U.S.A.) supplemented with 10 mM HEPES buffer, 5
1 1005 M b-ME, antibiotics, and 10% (v/v) FCS (Pan Sys- p24/51 104 cells calculated according to a p24 sandwich
assay), the yields of these proteins were significantlytems, Aidenbach, Germany). In a mixed lymphocyte-tu-
mor cell culture (MLTC), 3 1 107 responder cells were reduced as compared to the 29-kDa polyhedrin gene
product seen in wt-AcNPV-infected cells (Fig. 2, lane 12).cocultured with 1.5 1 106 syngeneic, peptide-pulsed
P815 cells (irradiated with 200 Gray) in 10 ml medium Specific detection of the chimeric proteins was per-
formed by Western blot analysis using monoclonal anti-in upright 25-cm2 tissue culture flasks in a humidified
atmosphere/7% CO2 at 377. Cytotoxic effector populations body 16/4/2 specifically recognizing Pr55
gag (Fig. 2B). The
presence of minor bands of lower molecular weight indi-were harvested after 6 days of in vitro culture and
washed twice. Serial dilutions of effector cells were cul- cated extensive intracellular cleavage of the chimeric
proteins by cellular proteases.tured with 2 1 103 51Cr-labeled targets in 200-ml round-
bottom wells. Specific cytolytic activity of cells was tested The chimeric polypeptides self-assembled to retrovi-
rus-like particles that budded from cells. This was evi-in short-term 51Cr-release assays against peptide-pulsed
targets. After a 4-hr incubation at 377, 100 ml of superna- dent after examination of SF9 insect cells that were in-
fected with the AcNPV recombinants. In all preparationstant were collected for g-radiation counting. The percent-
age of specific release was calculated as [(experimental tested, budding and release of chimeric VLP resembling
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of p24 in each fraction was determined by a p24 sand-
wich assay. As shown in Fig. 4, antigenic peaks at a
density of 1.14 to 1.18 g/cm3, typical for HIV, were identi-
fied in supernatants of cells expressing the wt-Pr55gag
gene product (Pr55), but not its myristoylation-deficient
form (Pr55M0) (Gottlinger et al., 1989; Wagner et al.,
1992a). The analysis of supernatants after infection of
HighFive cells with AcPr55V3-2, -3, or -4 and AcPr55V3/
CD4BR demonstrated a maximum of p24 antigen at iden-
tical densities (fractions 11–13) (Fig. 4B). However, com-
pared to the expression of the wt-Pr55gag, the total
amounts of chimeric antigens budding into the cell cul-
ture supernatants decreased by a factor of 2 to 4 de-
pending on the position of the gp120-derived epitopes
within the Pr55gag precursor. We also noted a clear corre-
lation between the gag chimeras leading to the formation
of morphologically irregular VLP (Pr55V3/CD4BR, Pr55V3-
2, Pr55CD4BR-3, Pr55CD4BRs-3), and a reduced releaseFIG. 1. Schematic drawing of the chimeric gag genes. (A) Position
of the gag and env coding sequences in the HIV-1 genome. Different of VLP to the cell culture supernatant. Among all con-
functional domains (p17, p24, p7, and p6) within the gag precursor structs tested, carboxy-terminal fusions of the foreign
protein (Pr55) and two immunologically relevant epitopes within the epitopes to the complete wild-type gag precursor repre-
external envelope glycoprotein gp120 (third variable domain V3, CD4-
sented the most efficient way to produce large quantitiesbinding region CD4BR) are indicated. (B) DNA sequences encoding
of chimeric VLP.the V3 domain (V3, amino acids 296–332), a short stretch (CD4BRs,
amino acids 419–444), and an extended region within the discontinu- Purified VLP from the antigenic peak fraction 12 were
ous CD4 binding domain of gp120 (CD4BR, amino acids 403–458) were characterized by SDS–polyacrylamide gel electrophore-
inserted into the gag gene to replace amino acids 211–241 (Pr55V3- sis followed by silver staining and immunoblot analysis
2, Pr55CD4BRs-2, Pr55CD4BR-2) or amino acids 436–471 (Pr55V3-3,
(Fig. 5). Silver staining of the separated antigen prepara-Pr55CD4BRs-3, Pr55CD4BR-3). A fusion of these sequences to the 3*
tions demonstrated the material to be at least 70 to 80%end of the gag gene resulted in the chimeric constructs Pr55V3-4,
Pr55CD4BRs-4, and Pr55CD4BR-4. A chimera, wherein amino acids pure. Major protein species were detected at a molecular
211 –241 were replaced by the V3 domain and part of the CD4-binding weight which was calculated for each chimeric protein,
region was fused to the carboxy-terminus of the gag gene was referred
to as Pr55V3/CD4BR. Abbreviations describing the different chimeric
genes are given at the right, the number of amino acids encoded by
the chimeric genes are indicated at the left side of the figure.
immature HIV virions was identified. Figure 3 gives a
representative example for the morphology of chimeric
VLP in which the V3 domain replaces amino acids 436 –
471 (Pr55V3-3). Particulate structures with a diameter
ranging from 100 to 140 nm were surrounded by a typical
plasma membrane and covered on the inner side by a
15- to 17-nm electron dense layer of chimeric Pr55gag. All
other chimeric VLP showed a similar EM morphology
except those which are based on the expression of
Pr55V3-2, Pr55CD4BRs-3, Pr55CD4BR-3, and Pr55V3/
FIG. 2. Analysis of SF9 cell lysates 3 days after infection with differentCD4BR. In these cases, more than half of all VLP deviated
recombinant AcNPVs (m.o.i.  10 per cell). SF9 cells were infectedfrom the typical retrovirus-like structure in size (100–250
with AcPr55V3-2 (lane 1), AcPr55V3-3 (lane 2), AcPr55V3-4 (lane 3),nm) and shape (data not shown). These data suggest
AcPr55V3/CD4BR (lane 4), AcPr55CD4BRs-2 (lane 5), AcPr55CD4BR-2
that the length and/or chemical properties of the gp120- (lane 6), AcPr55CD4BRs-3 (lane 7), AcPr55CD4BR-3 (lane 8),
derived epitopes influence the conformation and capacity AcPr55CD4BRs-4 (lane 9), AcPr55CD4BR-4 (lane 10). Noninfected cells
(lane 13) or cells infected either with recombinant AcNPVs expressingof the modified Pr55gag precursors to assemble and bud
Pr55gag (AcPr55, lane 11) or wt-AcNPV (lane 12) served as controls.as VLP from eukaryotic cells to a variable extent.
Polypeptides were separated by SDS 12%–PAGE and detected by Coo-Supernatants of HighFive insect cells harvested 3 days
massie staining (A) and immunoblotting using a p24-specific mono-
after infection with recombinant AcNPVs were analyzed clonal antibody (B). Arrows to the right indicate the position of wt-
by sucrose sedimentation analysis (Fig. 4). Twenty frac- Pr55gag (lane 11) and of the polyhedin protein (PH, lane 12). Sizes are
indicated in kilodaltons.tions were collected from each gradient and the amount
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FIG. 3. Ultrathin-section electron micrographs of SF9 cells harvested 3 days after infection (m.o.i.  10 per cell) with AcPr55V3-3. Details indicating
a slightly irregular shape of some released VLP are given in B.
FIG. 4. Analysis of the particle forming capacity of the Pr55gag chimeric polypeptides by sucrose sedimentation analysis. Recombinant proteins
released into the supernatants of SF9 cells 3 days after infection with the indicated AcNPV recombinants (m.o.i.  10 per cell) were quantified by
a p24 sandwich assay. Antigenic peaks containing enriched VLP were observed at a density (m) of about 1.14–1.18 g/cm3 (fractions 11–13). The
indicated density profiles represent the mean values of all measured gradients; standard deviations were always less than 1% of the means.
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sence of any adjuvant. Antibody titers to purified recombi-
nant proteins (p24CA, gp120) and to the synthetic pep-
tides (V3, CD4BR) were measured by ELISA. All three
groups (groups 3–5) generated substantial levels p24-
reactive antibodies already after the first booster injec-
tion (data not shown). In contrast, antibody responses to
recombinant gp120 and to the synthetic V3-37 peptide
were low and chiefly correlated with the position of the V3
domain within the Pr55gag carrier component. The highest
antibody titers were detected when the V3 sequence was
fused to the carboxy-terminus of the complete Pr55gag
precursor (Pr55V3-4). However, serum dilutions of 1/4
and 1/8 were necessary to neutralize homologous HIV-
1 by more than 90%, whereas, antisera raised against
FIG. 5. Analysis of the antigenic peak fractions after sucrose sedi- peptide V3-37 (Wagner et al., 1992b) neutralized the
mentation analysis. VLP were precipitated from fraction 12 of each
same virus at dilutions of 1/128 (group 1). Sera raisedgradient (see Fig. 4). (A) Aliquots were analyzed by SDS 12%–PAGE
against wt-Pr55gag VLP were nonneutralizing (group 2)followed by silver staining of the polypeptides. (B–D) Chimeric antigens
were detected by immunoblotting using monoclonal antibodies specifi- (data not shown). Administration of the VLP preparations
cally recognizing p24 (B) and the V3 domain (C). Chimeric antigens with alum neither increased the titer of reactive antibod-
containing the CD4-binding region were detected by a monospecific ies, nor the neutralizing properties of the tested antisera
antiserum (D). Lane 1, Pr55V3-2 VLP; lane 2, Pr55V3-3 VLP; lane 3,
(group 6). Administration of nonparticulate, monomericPr55V3-4 VLP; lane 4, Pr55V3/CD4BR VLP; lane 5, Pr55CD4sBR-2 VLP;
Pr55V3-4 antigens with and without alum were less im-lane 6, Pr55CD4BR-2 VLP; lane 7, Pr55CD4sBR-3 VLP; lane 8,
Pr55CD4BR-3 VLP; lane 9, Pr55CD4sBR-4 VLP; lane 10, Pr55CD4BR-4 munogenic than the corresponding VLP preparations
VLP. Precipitates of fraction 12 analyzing supernatants of cells infected (groups 7 and 8).
with AcPr55 (lane 11), wt-AcNPV (lane 12), or supernatants of unin- Similar results were obtained for chimeric VLP pre-
fected cells (lane 13) were included. Sizes are indicated in kilodalton.
senting the CD4BR (groups 9–14). High antibody titers
against the p24CA were measured, but titers of antibod-
ies specifically binding the CD4BR were low (dependingrespectively (Fig. 5A). Degradation products of molecular
on the position of the foreign epitope within the gagweights below 40 kDa were not observed. All chimeric
protein). The addition of sequences flanking the CD4BRpolypeptides including a Pr55-positive control were de-
epitope, including cysteine residues did not enhance thetected by antibody 16/4/2 specifically recognizing p24
immunogenicity of these epitopes for B cells (groups 12–within Pr55gag. Chimeric polypeptides including either the
14). Synergistic effects concerning the induction of aV3 domain (lanes 1–4) or the CD4-binding region (lanes
neutralizing antibody response either by combination of4–10) or both epitopes (lane 4) were specifically detected
a linear portion of the CD4 binding site and V3 domainby a V3-specific monoclonal antibody (Fig. 5C) or by a
in one VLP construct or by coimmunization with a mixturepolyclonal antiserum raised in rabbits against a peptide
of two different VLP preparations were not observedrepresenting amino acids 403–458 of the CD4 binding
(groups 15 and 16). Chimeric VLP are thus potent Pr55gagregion (Fig. 5D).
immunogens exhibiting intrinsic adjuvant properties, but
weak immunogens for generating a neutralizing immuneHumoral immune responses of rabbits to chimeric
response to the inserted env-derived epitopes.VLP
The capacity of chimeric VLP to induce an antibody Efficient priming of class I-restricted CTL responses
response to the Pr55gag carrier protein and to the inserted by chimeric Pr55V3 VLP
epitopes was investigated in rabbits (Fig. 6). Fifteen
groups (2–16) of three animals each received a priming Chimeric Pr55V3 VLP were injected i.p., i.v., or s.c.
without adjuvants into BALB/c mice (10 mg per mouse).immunization (i.m.) of recombinant antigen (50 mg/dose)
followed by two i.m. boosts at Days 28 and 56. One Twelve days postimmunization spleen cells or lymph
node cells were obtained from primed mice, transferredcontrol group (group 1) received 50 mg of a synthetic
37 mer V3-loop peptide (V3-37) (Wagner et al., 1992b), into culture, and restimulated with syngeneic, peptide-
pulsed, inactivated cells in a 5-day mixed lymphocyte-administered in combination with mineral oil (IFA) for
the following booster injections. A second control group tumor cell culture (MLTC). The H-2d mastocytoma cell
line P815 or the H-2d B lymphoma cell line A20 pulsed(group 2) was immunized according to the above immuni-
zation regimen with 50 mg of wt-Pr55gag VLP without adju- with the synthetic 16 mer V3 peptide (RIQRGPGRAFVT-
IGKI) were used as stimulator cells in the MLTC. Cellsvants. Groups 3–5 received three different preparations
of Pr55V3 chimeric VLP (Pr55V3-2, -3, or -4) in the ab- harvested from MLTC were tested for specific cytotoxic
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FIG. 6. Humoral immune response induced in rabbits. 16 groups (1–16) of three rabbits each were immunized three times in 4-week intervals
with 50 mg of the indicated antigens. All antigens except those administered to groups 1, 6, and 8 were injected in absence of adjuvants. Group 1
received peptide V3-37 emulsified in IFA; group 2 received Pr55 virus-like particles (VLP); groups 3–5 received different variants of chimeric Pr55V3
VLP. The influence of adjuvants and conformation of the antigens was investigated by using Pr55V3-4 VLP adsorbed to alum (6) or soluble Pr55V3-
4 protein in absence (7) and presence (8) of alum for the immunization. Groups 9–14 received VLP presenting two different parts of the CD4 binding
domain. Groups 15 and 16 were immunized with VLP containing both the V3 and CD4 binding domain (15) or with a combination of two different
types of VLP (16). Endpoint antibody titers of the immune sera to the V3 domain (V3), to a part of the CD4-binding region (CD4BR), to the complete
external glycoprotein gp120, and to the p24 capsid antigen (p24CA) are depicted as the reciprocal of the last dilution giving the threefold optical
OD as compared to the preimmune sera. The mean endpoint titers of three rabbits in each group are shown; error bars represent standard
deviations. Note the log-scale representation.
activity in a standard, short-term 51Cr-release assay. Cells was not detected in a primary MLTC in which lymph
node or spleen cells from unprimed BALB/c mice werefrom mice primed by a single injection of a low dose of
Pr55V3 VLP developed specific CTL reactivity, irrespec- cocultivated with peptide-pulsed stimulator cells (Fig.
7A). In vivo priming of CTL was thus required to inducetive of the route of antigen delivery (Figs. 7B–D). The in
vivo-primed and in vitro-restimulated cells lysed peptide- the specific cytolytic response. Effector cells of this re-
sponse expressed the CD3/CD40CD8/ phenotype be-pulsed but not unpulsed targets. Specific CTL reactivity
FIG. 7. Priming of class I-restricted cytotoxic T lymphocytes with Pr55V3-4 chimeric VLP. BALB/c mice were immunized subcutaneously (B),
intraperitoneally (C), or intravenously (D) with 10 mg Pr55V3-4 VLP. For control, mice were not immunized (A). Twelve days postimmunization spleen
cells or lymph node cells were obtained from primed mice and specifically restimulated in vitro in a 5-day mixed lymphocyte-tumor cell culture
(MLTC) using syngenic p815 mastocytoma cells pulsed with the synthetic V3 peptide as stimulator cells. The cytotoxic response was read out
against V3 peptide-treated (closed squares) or untreated (open squares) H-2d A20 B lymphoma cells as targets in a standard 4-hr 51Cr-release
assay. Mean values of triplicates obtained at an effector/target ratio of 20, 10, 5, and 2.5:1 are shown.
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DISCUSSION
Incorporation of foreign antigens into retroviral parti-
cles has been described previously using the gag pro-
teins of Rous sarcoma virus (RSV) and Moloney murine
leukemia virus (MLV) as a particulate carrier (Jones et
al., 1990; Weldon, Jr. et al., 1990). Recently, we identified
two domains within the Pr55gag precursor, which are dis-
pensible for the formation and release of virus-like parti-
cles from eukaryotic cells (Wagner et al., 1994). Herein,
we describe the construction, purification, and immuno-
logical characterization of chimeric gag-derived HIV-1 vi-
rus-like particles allowing the presentation of immuno-FIG. 8. Priming of class I-restricted cytotoxic T lymphocytes with
logical relevant epitopes derived from the external glyco-different doses of Pr55V3-4 chimeric VLP in presence and absence of
adjuvants. (A) BALB/c mice were immunized with an i.p. injection of 20 protein gp120 to the immune system.
mg (circles), 10 mg (squares), 1 mg (triangles), and 0.1 mg (diamonds) Gag:V3 hybrid particles, in which the complete p6 do-
of Pr55V3-4 VLP. (B) BALB/c mice were immunized with 10 mg of the main within Pr55gag was replaced by the V3 sequence,
chimeric Pr55V3-4 VLP either in absence of adjuvants (squares), or
have been demonstrated to be misdirected into the cellemulsified in IFA (circles), or absorbed in alum (triangles). The cytotoxic
nucleus, when expressed in insect cells (Griffiths et al.,response was determined against V3 peptide-treated (closed symbols)
or untreated (open symbols) H-2d A20 B lymphoma cells as targets in 1993). We neither observed migration of our chimeric
a standard 4-hr 51Cr-release assay. Mean values of triplicates obtained VLP into the nucleus nor could we find a V3-mediated
at an effector/target ratio of 20, 10, 5, and 2.5:1 are shown. interference with the intracellular trafficking. All pre-
sented constructs include either the complete p6 moiety
cause they were eliminated by treatment with anti-CD8 or at least the p6 carboxy-terminal domain within the
antibody plus complement, but were not affected by treat- Pr55gag precursor. Therefore, our results support the idea
ment with anti-CD4 antibody plus complement (data not by others that the p6 sequence is required for proper
shown).
To characterize the relative efficiency of this type of in
vivo priming of CTL by exogenous, particulate protein
antigen, we immunized mice i.p. with titrated doses of
20- to 0.1-mg chimeric VLP (Fig. 8A). For all recombinant
VLP tested, the maximal CTL response was reached by
immunization with 10 mg of antigen, with 20 mg giving
no further increase. However, specific CTL reactivity was
reproducibly detectable after a single injection of 0.1 mg
of the antigen. Hence, delivery of a low dose of this
antigen without adjuvants primed CTL efficiently in vivo.
To define the influence of adjuvants on the in vivo
priming of V3-specific CTL, BALB/c mice were immunized
with 10 mg of the chimeric Pr55V3-4 VLP, either in the
presence or absence of adjuvants. The VLP were either
emulsified in IFA or absorbed in aluminium hydroxide
(alum). Immunization of mice with the chimeric particles
associated with adjuvants inefficiently primed CTL. A rep-
resentative experiment is shown in Fig. 8B. Hence, both
tested adjuvants down-regulated CTL priming by recom-
binant protein antigen in vivo, as has been described in
comparable systems (Schirmbeck et al., 1994).
The position of the V3 epitope within the chimeric FIG. 9. Priming of class I-restricted cytotoxic T lymphocytes with
Pr55gag protein did not affect processing of this antigen different types of chimeric Pr55V3-4 VLP. BALB/c mice were immunized
for class I-restricted epitope presentation. Immunization with an i.p. injection of 1 mg Pr55V3-2 VLP (D), Pr55V3-3 (E), and Pr55V3-
4 (F). Control mice immunized with 50 mg 37 mer V3 peptide (A), 10by i.p. injection of three different constructs, i.e., Pr55V3-
mg recombinant gp160 (B), and 10 mg Pr55 VLP (C) were analyzed in2, -3, or Pr55V3-4 chimeric VLP stimulated comparable
parallel. The cytotoxic response was read out against V3 peptide-levels of class I-restricted, V3-specific CTL reactivity
treated (closed squares) or untreated (open squares) H-2d A20 B
(Figs. 9D–F). Administration of 50 mg of a 37 mer V3 lymphoma cells as targets in a standard 4-hr 51Cr-release assay. Mean
peptide, 10 mg gp160, and 10 mg Pr55 VLP did not result values of triplicates obtained at an effector/target ratio of 20, 10, 5, and
2.5:1 are shown.in the induction of V3-specific CTL.
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transport of the chimeric proteins to the cytoplasmic priming by injecting equimolar amounts of the immuno-
genic peptide. This was not observed in many indepen-membrane and an effivient release of VLP from the in-
fected cell (Gottlinger et al., 1991; 1993; Kondo et al., dent experiments, even when a 100- to 1000-fold higher
dose of the respective synthetic 16 mer V3 peptide was1995; Parent et al., 1995).
Immunization studies performed in rabbits demon- used. In contrast, the described experiments demon-
strate an efficient CTL priming by a single low dose im-strated that the addition of alum as an adjuvant to chime-
ric VLP does not significantly increase the induction of munization. This response was comparable to that
achieved previously after immunization with the corre-a humoral immune response. Moreover, a comparison
of chimeric Pr55V3-4 VLP versus soluble Pr55V3-4 poly- sponding Pr55V3 recombinant vaccinia virus (Wagner et
al., 1993).peptides on the induction of an antibody response clearly
revealed that the particulate nature of the VLP is essen- The entry of intact exogenous viral proteins to the en-
dogenous class I processing pathway has been de-tial for the stimulation of an antibody response. The mag-
nitude of the antibody response to the V3 domain or parts scribed for a variety of viral polypeptides such as influ-
enza hemagglutinin (Yewdell and Bennink, 1992) and nu-of the CD4-binding region inserted into or fused to the
Pr55gag carrier strictly depended on their position within cleoprotein (Wraith et al., 1987), poliovirus VP1 capsid
protein (Kutubuddin et al., 1992), proteins from humanthe gag polyprotein. In case of three different types of
Pr55V3 VLP, the V3-specific response varied from end- CMV virions (Riddell et al., 1991), and SV40 large T anti-
gen (Schirmbeck et al., 1992). In addition, particulatepoint titers of 1/80 (Pr55V3-2) to 1/2400 (Pr55V3-3) up to
1/9600 (Pr55V3-4). Comparable results were obtained for structures such as HBV surface antigen (HBsAg) parti-
cles or heterologous yeast Ty particles have been provenall of the chimeric VLP presenting either an extended or
truncated form of the CD4-binding region. Therefore, in to stimulate CD8/ CTL responses (Layton et al., 1993).
In the case of HBsAg particles, it has been demonstratedcontrast to previous reports (Luo et al., 1992; Griffiths et
al., 1993), we were in the case of groups 5, 11, 14, 15, convincingly that the uptake of the 22-nm lipoprotein par-
ticles by endocytosis followed by a novel endosomal/and 16 (Fig. 6) able to raise substantial levels of enve-
lope-specific antibodies. However, the antisera exhibited lysosomal processing pathway is required for class I-
restricted presentation of peptides derived from exoge-only weak neutralizing activity against the homologous
HIV-1LAI strain, which might be due either to an improper nous S-particles (Schirmbeck et al., 1995b).
The entry of an exogenous viral protein to the endoge-folding or limited accessibility of the inserted epitopes.
The finding that different types of Pr55V3 VLP induce a nous pathway may be masked, when it is injected in
conjunction with certain adjuvants. We have shown thatV3-specific CTL response considerably extends previous
reports by others and us (Griffiths et al., 1993; Schirm- immunization of BALB/c mice with different variants of
Pr55V3 VLP adjuvanted with aluminium hydroxide or min-beck et al., 1995a; Wagner et al., 1995) in that: (1) The in
vivo priming of a V3-specific CTL response in BALB/c eral oil inhibited or completely abrogated the induction
of a specific CD8/ CTL response. This observation ismice was detectable after a single s.c., i.p., or i.v. injec-
tion of 10 mg of recombinant Pr55V3 VLP; (2) in vivo in accordance with previous immunological analysis of
HBsAg particles reporting a suppressive influence of dif-priming of CD8/ CTL was achieved with a low dose of
VLP injected in absence of any adjuvants; (3) addition of ferent adjuvants on the induction of cytotoxic T cells
(Schirmbeck et al., 1994). However, the suppressivemineral oil (IFA) or alum to the VLP preparation consider-
ably reduced or completely abrogated the capability of mechanism operating in adjuvants-induced down regula-
tion of CTL priming to particulate Pr55V3 is not known.the VLP to induce a V3-specific CTL response; and (4)
the position within Pr55gag into which the V3 domain was The addition of certain adjuvants might alter the subset
of antigen presenting cells selected for the presentationinserted did not influence processing of the exogenous
antigen for MHC class I-restricted presentation of the of an antigenic peptide by APC. Alternatively, depending
on the type of antigen presenting cells, adjuvants mightantigenic V3 peptide.
The mechanism underlying the in vivo priming of V3- change the pattern of CD4/ T and or B cell subsets
stimulated in response to an antigen.specific CD8/ CTL by chimeric VLP is still unclear at
present. From a very simplistic point of view, induction The magnitude of the V3-specific CTL response
achieved by administration of different types of nonrepli-of CD8/ CTL requires processing of foreign proteins via
the endogenous processing pathway (Townsend and cating variants of chimeric Pr55V3 VLP was not influ-
enced by the position of the V3 domain within the Pr55gag-Bodmer, 1989; Monaco, 1992). A trivial explanation for
the in vivo priming of V3-specific CD8/ CTL would be that carrier moiety; the residues flanking the V3 loop domain,
hence, did not influence the processing of the exogenousa limited degradation of the VLP during the purification
procedure or following immunization by extracellular pro- antigen for MHC class I-restricted peptide presentation.
This result is in agreement with our previous data ob-teases generates peptides that allow MHC class I-re-
stricted presentation of the antigenic V3 peptide from an tained following immunization of BALB/c mice with re-
combinant vaccinia viruses expressing the correspond-APC. In this case, one would expect to observe CTL
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capable of contributing to immune dysfunction in HIV I-infected indi-ing Pr55V3 chimeric antigens. This suggests that the
viduals. J. Clin. Invest. 83, 1430–1435.exogenous and endogenous processing pathway result
Gotch, F. M., Nixon, D. F., Alp, N., McMichael, A. J., and Borysiewicz,
in the generation of a comparable set of antigenic pep- L. K. (1990). High frequency of memory and effector gag specific
tides (Wagner et al., 1993). cytotoxic T lymphocytes in HIV seropositive individuals. Int. Immunol.
2, 707–712.In summary, this study demonstrates that chimeric VLP
Gottlinger, H. G., Sodroski, J. G., and Haseltine, W. A. (1989). Role ofadministered in the absence of any adjuvant are potent
capsid precursor processing and myristoylation in morphogenesisimmunogens with respect to the induction of an HIV-
and infectivity of human immunodeficiency virus type 1. Proc. Natl.
specific CTL response but poor immunogens regarding Acad. Sci. USA 86, 5781–5785.
the neutralizing activity of the raised antisera. Work in Gottlinger, H. G., Dorfman, T., Sodroski, J. G., and Haseltine, W. A.
(1991). Effect of mutations affecting the p6 gag protein on humanprogress demonstrates that the capacity of recombinant
immunodeficiency virus particle release. Proc. Natl. Acad. Sci. USAVLP to induce HIV-1 neutralizing antibodies in addition
88, 3195–3199.to a CTL response may be significantly enhanced by
Gottlinger, H. G., Dorfman, T., Cohen, E. A., and Haseltine, W. A. (1993).
presenting large portions of envelope proteins on the Vpu protein of human immunodeficiency virus type 1 enhances the
surface of the VLP (Wagner et al., 1995). Similar strate- release of capsids produced by gag gene constructs of widely diver-
gent retroviruses. Proc. Natl. Acad. Sci. USA 90, 7381–7385.gies using DNA immunization to simultaneously express
Griffiths, J. C., Harris, S. J., Layton, G. T., Berrie, E. L., French, T. J.,env and gag resulted in the induction of both arms of
Burns, N. R., Adams, S. E., and Kingsman, A. J. (1993). Hybrid humanthe immune response (Lu et al., 1995). Future studies in
immunodeficiency virus Gag particles as an antigen carrier system:
appropriate primate models will assist to define the role Induction of cytotoxic T-cell and humoral responses by a Gag:V3
of humoral and cell-mediated immune responses in con- fusion. J. Virol. 67, 3191–3198.
Heeg, K., Kuon, W., and Wagner, H. (1991). Vaccination of class I majorferring protection.
histocompatibility complex (MHC)-restricted murine CD8/ cytotoxic
T lymphocytes towards soluble antigens: Immunostimulating-oval-
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